<address id="hfnfp"></address>

            <form id="hfnfp"></form>

                <form id="hfnfp"><listing id="hfnfp"></listing></form>

                <form id="hfnfp"><form id="hfnfp"></form></form>
                <address id="hfnfp"></address>

                      <address id="hfnfp"></address>

                      新聞動態   News
                      聯系我們   Contact
                      搜索   Search
                      你的位置:首頁 > 新聞動態 > 行業新聞

                      2024年全球抗體藥物偶聯物(ADC)市場將達到100億美元

                      2015-4-1 14:12:45      點擊:

                      2024年全球抗體藥物偶聯物(ADC)市場將達到100億美元

                      作者:tomato來源:生物谷2014-10-14 9:08:24

                      下載生物谷資訊App

                      關鍵詞: 抗體藥物偶聯物 ADC 市場

                      20141014 /生物谷BIOON/ --抗體藥物偶聯物(Antibody Drug Conjugates,ADC是一類新穎的治療藥物,正日益受到全球制藥公司的關注。ADC藥物由單克隆抗體和強效毒性藥物(toxic drug)通過生物活性連接器(linker)偶聯而成,是一種定點靶向癌細胞的強效抗癌藥物。由于其對靶點的準確識別性及非癌細胞不受影響性,極大地提高了藥效并減少了毒副作用。(另附生物谷文章:《抗體-藥物偶聯劑(ADCs)的研究進展與產業現狀》

                      近幾年,全球已掀起抗體藥物偶聯物(ADC)研發的熱潮。ADC類藥物被認為能夠更加高效和有效的治療疾病,在未來將成為治療疾病的重要手段。

                      根據全球知名市場調研公司Research & Markets發布的一份新報告,未來10年,ADC市場將經歷飛速發展。目前,由于僅有2ADC藥物(Adcetris,Kadcyla)上市,2014ADC市場市值預計將超過6億美元。未來10年,預計將有7-10ADC新藥上市,2024ADC市場將達到100億美元。

                      根據報告內容,當前,ADC市場仍處于起步階段,僅有2個藥物上市,即武田和西雅圖遺傳學公司的Adcetris和羅氏的Kadcyla。不過,已有數個ADC藥物處于臨床開發階段,其中大部分開發用于腫瘤適應癥。制藥公司非常熱衷于將創新的藥物分子添加至藥物管線,而極具新穎性的ADC藥物,提供了一個絕佳的機會。

                      盡管目前ADC市場中已有幾個大型制藥公司,但ADC開發的技術能力仍依賴于少數幾個技術提供商。西雅圖遺傳學公司(Seattle Genetics)和ImmunoGenADC領域的先驅,大部分在研ADC藥物采用了它們的技術,主要是通過技術授權協議獲得。在未來,該領域中預計將會達成更多的聯合開發協議。

                      隨著數個ADC藥物的預期上市,ADC市場中的投資預計將進一步增加。藥物開發商/風險投資商正在生物制劑領域投入大量資金,但投向ADC研發的比例仍有待觀察。隨著制藥巨頭尋求獲得ADC市場的競爭優勢,當前的市場格局將進一步演變。ADC市場未來增長機會十分可喜,但同時也存在著一些挑戰。

                      ——目前,僅有2ADC藥物(Adcetris,Kadcyla)上市,隨著銷售的預期增長,2014ADC市場市值預計將超過6億美元。未來10年,預計將有7-10ADC新藥上市,2024ADC市場將達到100億美元。

                      ——目前,約有45ADC藥物處于臨床開發。其中,約25%處于II/III期階段,而臨床前管線正在迅速擴張。

                      ——在研ADC藥物中,最常用到的細胞毒制劑包括阿里他。auristatin)、卡奇霉素(calicheamicin)、美登素(maytansine)和倍癌霉素(duocarmycin)。其中,阿里他汀占主導地位,約占在研ADC藥物的50%以上。

                      ——羅氏有10個在研ADC新藥,擁有最發達的ADC管線。在技術和創新方面,其他新近進入ADC市場的制藥公司包括牛津生物治療公司(Oxford BioTherapeutics)、Mersana Therapeutics、Abzena,這些公司提供的新穎技術,將幫助推動ADC市場的發展。

                      ——西雅圖遺傳學公司(Seattle Genetics)和ImmunoGen公司是最活躍的2家公司,為大量在研ADC藥物提供了專利性的ADC技術。

                      ——目前,有70%-80%ADC生產為外包(outsourced)。有能力開發連接器和細胞毒素的合同生產商數目非常有限,能夠提供ADC藥物共軛服務的合同生產商更為有限。

                      ——過去幾年中,已經開發了一些ADC技術。然而,更穩定的連接器和更強效的細胞毒素,將確保新一代ADC藥物具有改善的安全性和療效。(生物谷Bioon.com

                      本文系生物谷原創編譯整理,歡迎轉載!轉載請注明來源并附原文鏈接。謝謝!

                      英文原文:Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024

                      Antibody drug conjugates (ADCs) are a new class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies. Generally

                      addressed as the marriage of an antibody with a toxic drug / chemotherapy drug, these conjugates are believed to be more efficient and effective in the treatment of a

                      disease.

                      The ADC market is still in its infancy. At present, Adcetris and Kadcyla are the only two marketed drugs. However, there are several ADCs under development, with most

                      of them being developed for oncological indication. Pharmaceutical companies are keen to add innovative molecules to their diminishing product pipelines and ADCs

                      provide an attractive opportunity due to their novel nature.

                      Although the market now has presence of several large pharmaceutical companies, the technological capabilities for development of ADC still lies with a few technology

                      providers. Seattle Genetics and ImmunoGen are amongst the pioneers in the field of ADC, with most pipeline ADCs using their technology. Most development to date has

                      been carried under technology license agreements. However, we expect to see more co-development agreements in the future.

                      As more ADCs move from pipeline to the market, there is likely to be a further increase in investments in this area. Drug developers / venture capital firms are

                      investing huge amount of money in biologics and it remains to be seen what proportion of this will be directed towards ADCs. The current market landscape will

                      gradually evolve as large pharmaceutical companies look to gain competitive advantage in the ADC market. The future of the market is promising, though there are

                      several challenges to meet.

                      - Driven by the sales of Adcetris and Kadcyla (the two drugs currently available commercially), the ADC market is likely to be worth more than USD 600 million in 2014.

                      - About 45 molecules are currently in clinical development. Of these, approximately 25% are in Phase II or Phase III of development. As expected, the preclinical

                      pipeline is also gradually expanding.

                      - Most commonly used cytotoxins for ADCs under clinical development include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin dominates the market and

                      accounts for over 50% of ADCs in clinical development.

                      -Roche, with 10 molecules in clinical development, has the most developed pipeline of ADCs. Relatively new entrants such as Oxford BioTherapeutics, Mersana

                      Therapeutics, Abzena are likely to provide the necessary push (both in terms of technology and innovation).

                      - Seattle Genetics and ImmunoGen are the two most active companies offering their proprietary ADC technologies to a large number of ADCs under development.

                      - About 70%-80% of ADC manufacturing is currently outsourced. There are limited number of contract manufacturers with capabilities for development of linkers and

                      cytotoxins. In addition, even fewer CMOs provide conjugation services for ADC.

                      - Several technological developments have taken place in the recent past; more stable linkers and potent cytotoxins are likely to ensure that the next generation ADCs

                      have improved safety/efficacy profile.

                      - With around 7-10 new ADC commercial launches over the coming decade, we believe the overall market will be worth USD 10 billion annually by 2024.

                       

                      永久网站中的一级大黄毛片,videodesexo俄罗斯极品,真人裸交试看120秒,亚洲美女高清aⅴ视频免费